Although the human and societal burden and cost of COPD is staggering, there are few clinical tools that provide earlier diagnoses or a means to regionally monitor disease in a way that might lead to improved therapies and outcomes. In acknowledgement of the current gaps in COPD therapy, the objective of the Thoracic Imaging Network of Canada (TINCan) is to improve COPD patient phenotyping through imaging, to provide methods and imaging-based intermediate endpoints for the development of new treatments, and to evaluate disease progression and patient-based outcomes in COPD patients and those at risk of COPD. Here we summarize and outline the TINCan study protocol and describe our objectives. TINCan is a prospective study that aims to identify and quantify novel COPD phenotypes from thoracic computed tomography (CT) and thoracic hyperpolarized noble gas magnetic resonance imaging (MRI) in 200 ex-smokers, 50 years of age or greater, including asymptomatic ex-smokers with normal pulmonary function and Global initiative for chronic Obstructive Lung Disease (GOLD) Unclassified (U) , and GOLD stages I-IV patients. Baseline and 2-year follow-up measurements will be acquired using spirometry, plethysmography, diffusing capacity of the lung for carbon monoxide (DLCO), St. George's Respiratory Questionnaire (SGRQ), 6-minute walk test (6MWT), thoracic CT and hyperpolarized helium-3 ( 3 He) and xenon 129 ( 129 Xe) MRI. TINCan provides a unique opportunity to quantify and compare novel lung structure-function measurements and investigate their relationship with well-established clinical measurements and outcomes. Such intermediate endpoints of COPD may be used to stratify patients for personalized treatments and to develop new treatments to improve outcomes, a long-standing clinical goal.
Introduction
Chronic obstructive pulmonary disease (COPD) affects over 600 million people 1 and is the third leading cause of death worldwide.
2 Despite the huge societal, patient and health care system burden, 3,4 COPD remains largely underdiagnosed 5, 6 and undertreated. 7 Although COPD is currently diagnosed and its severity graded by nonfully-reversible airflow limitation, there is tremendous heterogeneity in the underlying regional abnormalities within and across COPD severity categories.
8 However, until recently, COPD patient measurements have been dominated by airflow and physiological measurements (e.g. inert gas washout tests 9 ), or invasive histological measurements and this has limited the scope of research related to regional COPD phenotypes and their effect on outcomes and disease pathogenesis.
Unlike spirometry and other measurements made at the mouth, pulmonary imaging provides quantitative, regional and independent measurements of the underlying disease contributions in COPD. 10, 11 It is well-established that x-ray computed tomography (CT) provides a way to non-invasively measure the extent and regional distribution of emphysema and airway wall thickening in COPD 10,12-14 CT measurements also correlate significantly with mortality, 11, [30] [31] [32] [33] [34] Unfortunately, unlike the case for many chronic diseases where in vivo imaging has been exploited to improve patient outcomes, the inclusion of imaging in the clinical workup and prospective study of COPD therapies remains very limited. between MRI and CT imaging phenotypes of COPD with exacerbations, and 4) determine whether MRI and CT phenotypes are predictors of longitudinal changes in pulmonary function measurements, lung volumes, symptoms and functional capacity. To our knowledge, this is the first such large patient group comparison of structure-function imaging with prospective crosssectional and longitudinal components. This study was designed to be complementary to larger ongoing COPD investigations and to address some of the important information gaps that remain. Here we describe the study plan and aims for TINCan and the potential impact of this study to improve our understanding of COPD patient phenotypes.
Methods

Participants
As shown in the schedule of study assessments in with normal pulmonary function. Thus far, a total of 75 ex-smokers without airflow limitation or GOLD U and 107 individuals with COPD, including GOLD stage I (n=22), GOLD stage II (n=49), GOLD stage III (n=29) and GOLD stage IV (n=7), have been enrolled. Participant recruitment was primarily performed by local academic pulmonologists, advertisement in local newspapers, community newsletters and a local atherosclerosis prevention clinic. All participants will provide written informed consent to the protocol that was approved by a local research ethics board and Health Canada and compliant with the Health Insurance Portability and Accountability Act. Review and documented consent will be performed during the follow-up visit prior to participant evaluations. The primary responsibility of a full-time research coordinator (certified by the Association of Clinical Research Professionals) included management of recruitment and scheduling as well as participant retention activities. Based on our previous experience with a pilot two-year longitudinal study where the retention rate was 90%, 41 we expect similar participant retention over the two-year follow-up period.
Pulmonary Function and Other Measurements
All participants will undergo, at baseline and at the two-year follow-up, post-bronchodilator spirometry and plethysmography, the St George's Respiratory Questionnaire (SGRQ), used with permission, 42 and a 6-minute walk test (6MWT) 43, 44 to measure the 6-minute walk distance (6MWD). Spirometry, plethysmography and diffusing capacity of the lung for For TINCan, 231 individuals were contacted and 208 individuals attended the baseline study visit. Of the 208 individuals who attended the baseline visit, 6 individuals refused consent, 16 individuals were excluded due to MRI incompatibilities and 4 individuals were excluded because they were unable to perform the 3 He gas inhalation and breath-hold. Complete visits, defined as one in which individuals were able to complete all study evaluations was performed for 182 individuals; 75 individuals did not have airflow limitation (FEV 1 /FVC≥0.70) and 107 individuals had COPD defined using spirometry according to GOLD criteria. 1 carbon monoxide (DLCO) will be measured using body plethysmography (MedGraphics Corporation, Minnesota, USA) with the attached Medgraphics gas analyzer according to American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines.
45-48 For all participants who complete the baseline study visit, the number of acute exacerbations requiring hospitalization or COPD-related hospitalizations will be reported using patient hospital records obtained with Cerner's PowerChart® (Cerner Corporation, Missouri, USA) up to 5 years prior to the initial participant baseline visit as well as during the follow-up period. 
CT Imaging
Thoracic CT will be acquired using a 64-slice (General Electric Health Care Milwaukee) CT system. Baseline CT images will be acquired with patients at inspiration breath-hold after inhalation of 1.0L medical grade nitrogen (N2) from a 1.0 L Tedlar® bag (Jensen Inert Products, New Jersey, USA) from functional residual capacity (FRC) using the same imaging protocol as the ECLIPSE study 39 and the same lung volume used with an MRI. We use a Tedlar® bag filled with N2 instead of room air for CT imaging because the hyperpolarized 3 He gas depolarizes when exposed to oxygen (O2) and therefore, the gas dispensing apparatus must remain completely free of O2 in order to avoid the potential for cross-contamination. The baseline CT is acquired at the same lung volume as used with an MRI to enable image co-registration; CT-MRI co-registration will allow us to investigate the relationship between morphological CT airway measurements and hyperpolarized noble gas MRI static ventilation measurements. In order to evaluate regional pulmonary gas trapping, as well as to differentiate regions of gas trapping due to emphysematous tissue destruction from small airway disease using inspiratory to expiratory image registration, 49 a full inspiration and full expiration CT will be performed at the two-year follow-up using the same imaging protocol as the COPDGene 37 and CanCOLD 38 studies. Importantly, the CT images acquired at the two-year longitudinal follow-up will not be used to evaluate longitudinal measurement changes. Both baseline and longitudinal CT will be used for investigating relationships between MRI and CT measurements.
All CT images will be quantified using the Pulmonary Workstation 2.0 (VIDA Diagnostics, Inc., Iowa, USA). CT structural airway measurements will include: 1) lumen area (LA), 2) airway wall area (AAW) and 3) wall area percentage (WA%) measured for the segmental and subsegmental airways, 10 and, 4) the square root of airway wall thickness for airways with an internal perimeter of 10mm (Pi10).
50 CT structural emphysema measurements will include: 1) the relative area with attenuation values below −950 Hounsfield units [HU] (RA950), 13 and, 2) the low attenuation cluster (LAC) analysis of connected regions with CT densitometry values < -950 HU.
51-53
At the two-year follow-up, inspiratory and expiratory CT images will be co-registered to regionally identify normal lung, emphysema and air trapping as recently described.
49
MR Imaging Hyperpolarized
3 He MRI will be acquired using a 3.0 Tesla MR750 system (General Electric Health Care, Milwaukee, WI USA). Participants will undergo breathhold imaging for acquisition of conventional 1 H MRI, 3 He static ventilation MRI and 3 He diffusion-weighted MRI. Conventional 1 H MRI will be acquired during 1.0L breath-hold of N2 from a 1.0 L Tedlar® bag from FRC. 3 He static ventilation and diffusion weighted imaging will be performed following inhalation of a 3 He/N2 gas mixture ( 3 He dose = 5 ml/kg body weight) from a 1.0 L Tedlar® bag from FRC as previously described.
25 At visit 2, a hyperpolarized 129 Xe MRI will also be acquired on the same system as 3He MRI using 129 Xe gas doses (50/50 129 Xe/ 4 He) administered in 1.0L Tedlar® bags with 129 Xe MRI static ventilation and diffusionweighted images acquired, as previously described.
34
There was not a commercially-available 129 Xe polarizer that was approved for human participants during baseline enrollment, and therefore, hyperpolarized 129 Xe was not performed at visit 1 for all participants. However, a small proof of concept study was performed in 10 TINCan COPD participants at visit 1 as previously described.
All MR images will be evaluated using custom-built software generated using MATLAB R2007b (The Mathworks Inc., Massachusetts, USA). For 3 He and 129 Xe MRI static ventilation images, regions of signal void or ventilation defects will be quantified as the ratio of the ventilation defect volume (VDV) to the thoracic cavity volume (segmented from 1 H MRI) to generate the whole lung ventilation defect percentage (VDP) 11,54 ; 3 He and 129 Xe apparent diffusion coefficient (ADC) maps will also be generated from diffusion-weighted images using custom built software (MATLAB R2007b) .
55
Figure 2 shows for 2 representative asymptomatic ex-smokers with normal pulmonary function and 2 representative COPD participants at baseline, the CT density mask highlighting areas with CT densitometry values less than -950 HU, CT low attenuation clusters registered to the 3D reconstruction of the CT airway tree for measurement of airway dimensions. 
Data and Statistical Analysis Plan
There are 4 key objectives for the TINCan study and these are enabled by the statistical analysis plan. First, we will determine the significant cross-sectional univariate and multivariate relationships for 3 He with 129 Xe MRI and CT-derived phenotypes of airway and parenchymal abnormalities. Pearson correlation coefficients and linear regression will be performed to determine the univariate relationships for baseline 3 He For the COPD ex-smokers, significantly greater emphysema extent is demonstrated by the highlighted areas on the CT density mask and bright ADC maps in Participant 4 (76 year-old female, FEV1=79%pred, FEV1/FVC=64%, DLCO=63%pred, RA950=33%, VDP=36%, ADC=0.63cm 2 /s), while a lesser extent is observed for Participant 3 (76 year-old female, FEV1=52%pred, FEV1/FVC=42%, DLCO=18%pred, RA950=1%, VDP=17%, ADC=0.31cm 2 /s). and 129 Xe gas distribution measurements (regional and whole lung VDV, VDP) with CT airway disease measurements and all other participant measurements.
Multivariate linear regression models will also be constructed for predicting SGRQ total score and 6MWD using CT (Pi10, RA950) and 3 He MRI (VDP, ADC) phenotype measurements, adjusted for sex, BMI, FEV1, and DLCO.
Second, we will determine the longitudinal changes and relationships for 3 He MRI-derived phenotypes of airway and parenchymal abnormalities with other COPD measurements (SGRQ, 6MWD, spirometry, plethysmography and DLCO). We will determine the significant longitudinal changes for 3 He MRI measurements using paired two-tailed t-tests. Pearson correlation coefficients and linear regression analyses will be performed to determine the relationships between the change in 3 He MRI measurements with the longitudinal change in physiological measures (FEV1, FEV1/ FVC, RV, DLCO), functional capacity (6MWD) and quality of life (SGRQ) measurements. We previously performed and reported the results of a pilot longitudinal study in 15 ex-smokers with COPD that demonstrated statistically significant 3 He ADC and VDP worsening in 2 years.
41 Based on this pilot study, with 100 COPD participants enrolled thus far and a longitudinal retention rate of 90% expected, this study has sufficient power to detect significant longitudinal changes for 3 He MRI measurements (α=.05, ß=0.20 and power=.80).
Third, the associations between imaging phenotypes of COPD with exacerbations will be evaluated. To accomplish this, a zeroinflated Poisson (ZIP) model will be used to determine the relationship between selected variables with COPD exacerbations, including hospitalization and death. The variables that will be included in the regression include: age, sex, BMI, smoking status, FEV1, DLCO, RV, SGRQ, 6MWD, CT RA950, CT WA%, 3 He MRI VDP, and 3 He MRI ADC. We have recently evaluated the association between imaging phenotypes of COPD with the number of hospitalizations and demonstrated that over a 5-year period, 58 hospitalizations occurred. also reported that 3 He VDP was a significant predictor of hospitalization due to COPD exacerbation.
56
Therefore, based on this study we are powered to detect statistically significant associations between 3 He MRI measurements with all COPD acute exacerbations, including those that resulted in treatment, emergency department visits and hospitalizations, as well as COPD-related mortality.
Finally, we will determine whether MRI and CT phenotypes are predictors of longitudinal changes in pulmonary function measurements, lung volumes, symptoms and functional capacity. Using mixed linear regression analyses adjusted for cofounders, we will determine which baseline imaging phenotype measurements have the strongest relationship with the longitudinal changes in health status (SGRQ), functional capacity (6MWD) and FEV1. Cofounders will include age, sex, smoking status, BMI, and baseline FEV1. In a similar manner we will also use hierarchical clustering models (Principal Component analysis) and generate icicle plots (showing cases as rows and number of clusters as columns) and dendograms (or hierarchical tree diagrams). Principal component analysis using hierarchical clustering is appropriate for smaller samples (typically < 250) and we will generate a dataset for all evaluable participants with 3 He and 129 Xe MRI structural and functional variables as well as CT-derived variables. In this way, we can attempt to determine which clusters of imaging and other measurements are the predictors of longitudinal progression and outcomes.
Discussion
In COPD, the current gold standard approach for evaluating disease severity, disease progression and treatment response relies on lung function measurements that provide little information about the underlying morphological, anatomical and functional abnormalities that result in symptoms, airflow limitation and adverse outcomes. To address this critical gap in knowledge, TINCan was developed and implemented. The major anticipated value of TINCan is an enhanced understanding of COPD-imaging phenotypes, and their relationship to well-established measurements of COPD and subclinical disease and disease progression. In addition, we hypothesize that non-invasive COPDimaging phenotypes directly reflect the underlying abnormalities in COPD and these can be used as intermediate endpoints in the development of new treatment approaches.
One important technical goal for TINCan is to provide tools and methods that streamline image analysis workflow to accelerate the translational potential of pulmonary functional MRIs. Therefore, we focused on developing image segmentation and registration tools to quantify measurements with high precision for detecting small measurement changes in treatment or longitudinal studies. Towards this goal, we developed a multi-step, semi-automated 3 He-1 H registration and segmentation method 57 and demonstrated that it provides excellent inter-/intra-observer precision and good agreement with expert observers' manual measurements.
With the development of image analysis tools underway, we can apply these tools to the TINCan cohort and be confident that the longitudinal changes measured are likely due to disease changes. Another important goal of TINCan is to provide a better understanding of the early or mild subclinical disease observed in ex-smokers with normal spirometry. We recently demonstrated that abnormal DLCO in exsmokers without COPD was related to worse health status, functional capacity and elevated 3 He ADC consistent with early emphysema revealed by 3 He MRI but not CT.
58 At the 2-year follow-up, we will determine whether such smokers with 3 He MRI evidence of early or mild emphysema (but without airflow limitation) show evidence of progressive disease.
For a small group of participants we have incorporated hyperpolarized 129 Xe MRI as part of the baseline visit to test hypotheses related to potential differences in 129 Xe and 3 He MRI ventilation. To better understand any potential differences between 3 He and 129 Xe MRI gas distribution, we quantitatively compared 3 He and 129 Xe MRI in COPD participants and observed that 129 Xe VDP was significantly greater than 3 He VDP.
34
We also observed that the regions of decreased 129 Xe ventilation were spatially and significantly correlated with regions of emphysema.
33 Taken together, these important findings suggest that 129 Xe gas may be more sensitive to changes in both the airways and parenchyma in COPD, and therefore may be more sensitive than 3 He for detecting changes at the 2-year follow-up.
The important next step of the TINCan cohort is to complete enrollment and then follow-up with all participants in order to evaluate longitudinal changes. We will identify whether MRI phenotypes detect significant disease progression, how changes in MR imaging-derived measures relate to changes in physiologic and health outcome measurements, and determine which baseline imaging phenotypes can predict declines in quality of life, functional capacity and physiologic measurements. We will also determine whether imaging phenotypes can independently identify individuals with more frequent exacerbations and more rapid declines in lung function. In contrast to other cohort studies of COPD,
37-40
TINCan's novelty stems from its incorporation of emerging non-radiation-based imaging measurements in addition to conventional CT. These emerging imaging methods have the potential to provide complementary quantitative information regarding subclinical and clinical COPD pathophysiologies that may eventually allow for more personalized treatment. Another strength of TINCan is the inclusion of individuals often excluded from COPD cohort studies. For example, TINCan includes a relatively large group of ex-smokers without COPD.
Identifying imaging phenotypes that can characterize these unique pathologies noninvasively and evaluate their relationships with disease progression and exacerbations is an important goal for the TINCan study.
In conclusion, here we describe the largest prospective, longitudinal pulmonary structure-function imaging study of COPD planned to-date using emerging MRI and CT imaging methods. Upon completion we will have a better understanding of the relationships between imaging phenotypes with well-established lung function and health status measurements, as well as outcomes, in a well-defined and relatively large group of ex-smokers. Finally, once complete, the resulting validated imaging measurements may be considered as intermediate endpoints for future COPD treatment studies to better target therapy, a long-standing research and clinical goal for COPD.
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